BioCentury | Aug 6, 2020
Finance

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

Cytokinetics in deals with Chinese biotech, investor  Cytokinetics Inc. (NASDAQ:CYTK) said it could receive $250 million in committed capital and $200 million in milestones via a series of deals with Ji Xing Pharmaceuticals Ltd. and...
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...
BioCentury | May 9, 2020
Translation in Brief

Antigens for COVID-19 serological testing; plus mapping glycans on SARS-CoV-2 spike, tumor sampling method and therapy for Parkinson’s

SARS-CoV-2 antigens beyond the spike protein  Described in a medRxiv preprint, researchers from the University of Hong Kong identified SARS-CoV-2 antigens beyond the spike protein that could be used to detect antibodies at early time...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Apr 29, 2020
Emerging Company Profile

Taysha: Applying AAV9 across the CNS

Taysha launched with a $30 million seed round and a team of former AveXis leaders ready to parlay their experience with Zolgensma into a broad pipeline of AAV9-based gene therapies for other CNS disorders. The...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Apr 16, 2020
Translation in Brief

SARS-CoV-2 fluorescent tool for drug development; plus Alzheimer's biomarkers, Nature, National Academies and Pylum

DNA-based tool for developing COVID-19 countermeasures University of Texas Medical Branch researchers have created a fluorescent SARS-CoV-2 DNA clone as a reporter tool for preclinically assessing COVID-19 vaccines and treatments. Described in Cell Host and...
Items per page:
1 - 10 of 1337
BioCentury | Aug 6, 2020
Finance

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing...
BioCentury | Aug 5, 2020
Emerging Company Profile

Nura reveals neuroprotective lead target, first part of its neurology one-two punch

Nura Bio emerged from stealth last week with a $73 million series A and strategy to tackle neurological disorders based on two prevailing theories -- increasing neuroprotection and reducing neuroinflammation. Led by Vir and Biogen...
BioCentury | Aug 1, 2020
Emerging Company Profile

VIB spinout ExeVir targeting COVID-19 with single-domain antibody technology

Nearly 20 years since the launch of Ablynx, VIB has spun out its fourth company with a camelid-derived antibody platform and its first to deploy the technology as a countermeasure against pandemic threats. ExeVir, which...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

Cytokinetics in deals with Chinese biotech, investor  Cytokinetics Inc. (NASDAQ:CYTK) said it could receive $250 million in committed capital and $200 million in milestones via a series of deals with Ji Xing Pharmaceuticals Ltd. and...
BioCentury | Jun 4, 2020
Emerging Company Profile

Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round

Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively...
BioCentury | May 9, 2020
Translation in Brief

Antigens for COVID-19 serological testing; plus mapping glycans on SARS-CoV-2 spike, tumor sampling method and therapy for Parkinson’s

SARS-CoV-2 antigens beyond the spike protein  Described in a medRxiv preprint, researchers from the University of Hong Kong identified SARS-CoV-2 antigens beyond the spike protein that could be used to detect antibodies at early time...
BioCentury | May 2, 2020
Management Tracks

Catalent’s Boerman becomes president of cell and gene therapy; plus Stanford, Intellia, Cortexyme, CZ Biohub, Grail and more

Catalent Inc. (NYSE:CTLT) said Manja Boerman will become president of cell and gene therapy, succeeding Pete Buzy, who will continue as chairman of the gene therapy business. Boerman was president of the biotech’s European biologics...
BioCentury | Apr 29, 2020
Emerging Company Profile

Taysha: Applying AAV9 across the CNS

Taysha launched with a $30 million seed round and a team of former AveXis leaders ready to parlay their experience with Zolgensma into a broad pipeline of AAV9-based gene therapies for other CNS disorders. The...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...
BioCentury | Apr 16, 2020
Translation in Brief

SARS-CoV-2 fluorescent tool for drug development; plus Alzheimer's biomarkers, Nature, National Academies and Pylum

DNA-based tool for developing COVID-19 countermeasures University of Texas Medical Branch researchers have created a fluorescent SARS-CoV-2 DNA clone as a reporter tool for preclinically assessing COVID-19 vaccines and treatments. Described in Cell Host and...
Items per page:
1 - 10 of 1337